RxDoctor Payments DataLook up a doctor →

Luther Corley, MD

Pulmonary Disease · Huntsville, ALNPI 1790861292

Payments from drug & device makers

$86,499in general payments, 2019–2025

Across 479 payments — averaging $180.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$73K
  • Regeneron Healthcare Solutions, Inc.$4K
  • Pulmonx Corporation$3K
  • GSK$2K
  • Insmed, Inc.$901
  • AstraZeneca$884
  • plus $4K from 30 others

What the payments were for

  • Consulting fees$2,2503%
  • Speaking & faculty fees$66,66977%
  • Travel & lodging$5,3916%
  • Food & beverage$11,99914%
  • Education$1910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,499 in reported general payments places this provider in the 90th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$127,281
Medicare patients
605
Services billed
4,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab104$401,391
Trelegy ElliptaFluticasone/Umeclidin/Vilanter374$363,929
XolairOmalizumab71$178,559
Breztri AerosphereBudesonide/Glycopyr/Formoterol176$126,635
OfevNintedanib Esylate14$109,041
Breo ElliptaFluticasone/Vilanterol227$106,796
NucalaMepolizumab27$92,947
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr79$58,935
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate178$46,826
Spiriva RespimatTiotropium Bromide47$38,397
SymbicortBudesonide/Formoterol Fumarate114$37,063
Combivent RespimatIpratropium/Albuterol Sulfate54$33,404
Stiolto RespimatTiotropium Br/Olodaterol Hcl36$26,600
Advair HfaFluticasone Propion/Salmeterol52$25,062
Arnuity ElliptaFluticasone Furoate89$24,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta$1,572$670,500852 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$731$207,441151 claims
Genentech, Inc.Xolair$85$178,55971 claims
AstraZenecaBreztri Aerosphere, Symbicort$884$163,699290 claims
PfizerEliquis$328$21,30135 claims
MerckDulera$63$17,45937 claims
Johnson & JohnsonXarelto$14$15,89215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →